Interleukin-1 receptor-associated kinase 4 (IRAK-4) (IRAK-4)

Interleukin-1 receptor-associated kinase 4 (IRAK-4) is a critical serine/threonine kinase that acts as a central node in the Toll-like receptor (TLR) and Interleukin-1 receptor (IL-1R) signaling pathways [1, 2, 5]. It is essential for the initiation of the innate immune response, where it facilitates the formation of the "Myddosome" complex with MyD88 and other IRAK family members [2, 4, 5]. This complex triggers downstream signaling through NF-κB and MAPK pathways, leading to the production of pro-inflammatory cytokines [3, 14]. Dysregulation or overactivation of IRAK-4 is linked to various inflammatory and autoimmune conditions, such as rheumatoid arthritis and lupus, as well as certain hematologic malignancies, particularly those with MYD88 mutations [3, 10, 14]. Therapeutic strategies include small-molecule kinase inhibitors and proteolysis-targeting chimeras (PROTACs) that degrade the protein to address both its catalytic and scaffolding functions [3, 4]. While targeting IRAK-4 offers significant therapeutic potential, safety concerns primarily involve an increased susceptibility to specific bacterial infections, reflecting its vital role in innate immunity [5, 8].

Other names

IRAK4REN64NY-REN-64IPD1IMD67Interleukin-1 receptor-associated kinase 4

Kinase inhibition (ATP-competitive) and targeted protein degradation (PROTAC).